P Jeffrey Conn Selected Research

Glutamic Acid (Glutamate)

1/2022	Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
1/2021	Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
1/2019	Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function.
10/2017	Role of mGlu5 Receptors and Inhibitory Neurotransmission in M1 Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia.
1/2016	Neurobiological Insights from mGlu Receptor Allosteric Modulation.
8/2015	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
2/2015	Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.
7/2014	Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅).
5/2014	Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.
1/2013	Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

P Jeffrey Conn Research Topics

Disease

72	Schizophrenia (Dementia Praecox) 12/2023 - 02/2002
32	Parkinson Disease (Parkinson's Disease) 01/2023 - 06/2002
19	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 10/2008
12	Catalepsy 01/2021 - 10/2008
8	Nervous System Diseases (Neurological Disorders) 11/2022 - 09/2008
7	Cocaine-Related Disorders (Cocaine Addiction) 01/2017 - 03/2010
6	Dyskinesias (Dyskinesia) 01/2023 - 12/2009
6	Central Nervous System Diseases (CNS Diseases) 08/2021 - 07/2007
6	Psychotic Disorders (Schizoaffective Disorder) 03/2015 - 11/2003
5	Brain Diseases (Brain Disorder) 12/2019 - 02/2015
4	Substance-Related Disorders (Drug Abuse) 08/2023 - 11/2012
4	Neurodevelopmental Disorders 01/2022 - 01/2017
4	Rett Syndrome (Rett's Disorder) 01/2022 - 01/2017
4	Neurobehavioral Manifestations 01/2021 - 05/2010
4	Seizures (Absence Seizure) 01/2019 - 08/2009
3	Cognitive Dysfunction 01/2023 - 05/2013
3	Movement Disorders (Movement Disorder) 08/2021 - 11/2014
3	Dystonia (Limb Dystonia) 08/2021 - 08/2009
3	Autistic Disorder (Autism) 01/2016 - 09/2012
3	Fragile X Syndrome (Martin Bell Syndrome) 01/2016 - 01/2011
3	Mental Disorders (Mental Disorder) 01/2010 - 12/2005
2	Depressive Disorder (Melancholia) 01/2023 - 01/2021
2	Anhedonia 01/2020 - 01/2019
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2019 - 03/2015
2	Disease Progression 01/2018 - 12/2009
2	Bipolar Disorder (Manic Depressive Psychosis) 11/2015 - 01/2015
2	Choriocarcinoma 11/2004 - 10/2003
1	Cerebellar Diseases (Cerebellar Syndrome) 01/2023
1	Opioid-Related Disorders (Opiate Addiction) 01/2022
1	Treatment-Resistant Depressive Disorder 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2020
1	Mood Disorders (Mood Disorder) 01/2020
1	Obesity 01/2019
1	Binge-Eating Disorder (Binge Eating Disorder) 01/2019
1	Alcoholism (Alcohol Abuse) 01/2018
1	Huntington Disease (Huntington's Disease) 01/2018
1	Lubs X-linked mental retardation syndrome 01/2018
1	Syndrome (Syndromes) 01/2017
1	Dementia (Dementias) 01/2017
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 10/2016

Drug/Important Bio-Agent (IBA)

37	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2022 - 02/2002
30	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2022 - 01/2008
16	Glutamic Acid (Glutamate)FDA Link 01/2022 - 12/2005
15	Antipsychotic Agents (Antipsychotics)IBA 12/2023 - 02/2002
12	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2022 - 02/2002
11	Cholinergic Agents (Cholinergics)IBA 08/2023 - 02/2002
11	Haloperidol (Haldol)FDA LinkGeneric 01/2021 - 11/2008
7	Levodopa (L Dopa)FDA LinkGeneric 01/2023 - 12/2009
7	metabotropic glutamate receptor 2IBA 01/2018 - 02/2006
7	N-Methylaspartate (NMDA)IBA 12/2016 - 02/2002
6	metabotropic glutamate receptor 3 (mGluR3)IBA 12/2023 - 07/2006
6	Dopamine (Intropin)FDA LinkGeneric 08/2023 - 02/2002
6	LigandsIBA 01/2022 - 12/2009
6	Muscarinic M4 ReceptorIBA 10/2018 - 01/2014
6	Glutamate Receptors (Glutamate Receptor)IBA 12/2016 - 01/2003
6	Metabotropic Glutamate 5 ReceptorIBA 10/2016 - 10/2013
6	metabotropic glutamate receptor 4IBA 01/2016 - 08/2003
5	Neurotransmitter Agents (Neurotransmitter)IBA 08/2021 - 12/2011
4	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2023 - 12/2012
4	Muscarinic M1 ReceptorIBA 01/2019 - 11/2014
3	Antidepressive Agents (Antidepressants)IBA 01/2023 - 01/2020
3	Dizocilpine Maleate (Dizocilpine)IBA 01/2022 - 03/2016
3	Methyl-CpG-Binding Protein 2IBA 01/2022 - 01/2017
3	metabotropic glutamate receptor 7IBA 01/2021 - 03/2010
3	Proteins (Proteins, Gene)FDA Link 10/2018 - 12/2011
3	Amphetamine (Amfetamine)FDA LinkGeneric 10/2018 - 07/2014
3	Cocaine (Cocaine HCl)IBA 01/2017 - 01/2011
3	Reserpine (Serpasil)FDA Link 03/2013 - 11/2008
2	Dopamine Receptors (Dopamine Receptor)IBA 01/2023 - 01/2021
2	Adenosine (Adenocard)FDA LinkGeneric 01/2023 - 02/2012
2	gamma-Aminobutyric Acid (GABA)IBA 01/2022 - 08/2015
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022 - 11/2021
2	Muscarinic AntagonistsIBA 08/2021 - 11/2014
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021 - 02/2002
2	Cholinergic ReceptorsIBA 01/2019 - 12/2012
2	benzocycloheptapyridineIBA 01/2018 - 01/2013
2	Phencyclidine (Angel Dust)IBA 10/2017 - 02/2002
2	Clozapine (Clozaril)FDA LinkGeneric 03/2016 - 11/2003
2	N-(3-chlorophenyl)picolinamideIBA 08/2015 - 02/2012
2	Cholinergic Antagonists (Anticholinergics)IBA 11/2014 - 05/2010
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 11/2012 - 11/2004
2	N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamideIBA 03/2012 - 08/2009
2	VU 0155041IBA 09/2009 - 11/2008
2	Glycine Plasma Membrane Transport ProteinsIBA 11/2004 - 10/2003
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2023
1	VU6019650IBA 01/2022
1	Ketamine FDA LinkGeneric 01/2021
1	VU0652957IBA 03/2019
1	Hydroxyl RadicalIBA 09/2018
1	EndocannabinoidsIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	AminesIBA 01/2018
1	VU0467485IBA 02/2017
1	Neuroprotective AgentsIBA 01/2017
1	VU0476406IBA 01/2017
1	PirenzepineIBA 05/2016
1	Divalent CationsIBA 05/2016
1	Hypnotics and Sedatives (Sedatives)IBA 03/2016

Therapy/Procedure

12	Therapeutics 01/2022 - 06/2002
3	Drug Therapy (Chemotherapy) 01/2018 - 03/2010